Nonmydriatic Fundus Cameras Market Is Projected To Grow To US$ 323.71 Million By 2034 At A 6.0% CAGRJain and Becker have served on the council together since 2020.
President Donald Trump is returning to the White House, convinced – after a close encounter with an assassin’s bullet – that he had God on his side in the election. While opinions differed on that theological question, Trump clearly drew strong support from voters who frequented pews. In Washington Post exit polls, he received 56 percent of the Catholic votes, while 41 percent backed Vice President Kamala Harris. In 2020, 52 percent of self-identified Catholics supported Joe Biden, with 47 percent for Trump. As always, Trump fared well with Protestants and “other Christians,” with 62 percent supporting him, as opposed to 37 percent for Harris. She won 60 percent of the votes of non-Christian believers, while Trump had 33 percent – up 4 percent from his showing in 2020. Thus, members of Religion News Association selected the 2024 presidential election as the year’s top national religion story. The 2024 poll of religion-news professionals was dominated by analysis of national and international news, as opposed to specific headlines and events, with a strong emphasis on trends among religious conservatives. Yet, Trump’s wins among religious believers – as well as gains among Latinos and Black men – were only one side of this drama, stressed Jessica Grose of the New York Times opinion staff. Democrats should note the “large and growing religious group that is already in their corner: the Nones,” she noted, referring to religiously unaffiliated Americans. “According to new data from the Public Religion Research Institute ... 72 percent of the religiously unaffiliated voted for Kamala Harris. Melissa Deckman, the chief executive of PRRI, shared a more granular breakdown of unaffiliated voters with me over email: 82 percent of atheists, 80 percent of agnostics and 64 percent of those who said they had no particular faith voted for Harris.” However, key voters rejected Democratic Party stands on many cultural and moral issues, noted Ruy Teixeira, a veteran Democrat strategist. In a Blueprint2024 survey, the top reason “swing” voters gave for rejecting Harris was that she seemed “more focused on transgender issues” than middle-class needs. Thus, one Trump ad proclaimed: “Kamala is for they/them. President Trump is for YOU.” Writing for The Free Press, Teixeira noted clashes on similar hot-button issues. He concluded: “If the Democrats’ liability on a range of cultural issues is so clear, why do so many party members refuse to admit the obvious problem?” The RNA national-news Top 10 list included: (2) Nearly two-thirds of Jews surveyed said they felt less safe in 2024, facing tensions over the Israel-Hamas war and increased news reports about antisemitic speech, especially at colleges and universities, as well as increased verbal and physical violence, including the shooting of a Jew walking to a Chicago synagogue. (3) Fighting in the Middle East strained support for Democrats among Jews and Muslims. Debates raged about the party’s support for Israel, while Muslims denounced ongoing U.S. support and weapons supplies to Israel. (4) In church-state news, Louisiana Gov. Jeff Landry signed a law requiring Ten Commandments displays in public classrooms, and Oklahoma’s top education official told schools to incorporate the Bible into lessons. Meanwhile, debates continue on “parental rights” claims on many moral questions, especially transgender issues. (5) Concerns rose among progressive activists about the power of “Christian nationalism” in American life, leading to a surge in press coverage. (6) The Alabama Supreme Court ruled that frozen embryos can be considered children. Facing a backlash – even among political conservatives – Alabama Gov. Kay Ivey signed legislation shielding in vitro fertilization providers from liability. (7) Activists noted rising reports of Islamophobia linked to the Gaza war. The Biden administration announced policies against anti-Muslim bias and hate crimes. (8) In seven states, voters expanded or reinforced abortion access. In three states, voters upheld abortion restrictions, the first to do so by referendum since the U.S. Supreme Court overturned Roe v. Wade in 2022. (9) After decades of fierce doctrinal debate, the shrinking United Methodist Church repealed its stance that homosexuality is “incompatible with Christian teaching” and backed openly LGBTQ+ clergy and same-sex marriages. (10) America’s increasingly fluid religious chemistry became obvious in politics, the RNA noted, with “Kamala Harris, a progressive Baptist married to a Jewish man and influenced by the religions of her mother’s native India” facing “Donald Trump, a non-denominational Christian with strong support from evangelicals and married to a Catholic.” Also, there was J.D. Vance, a Catholic convert married to a Hindu, and Tim Walz, a former Catholic who joined the liberal Evangelical Lutheran Church in America. Terry Mattingly is Senior Fellow on Communications and Culture at Saint Constantine College in Houston. He lives in Elizabethton, Tennessee, and writes Rational Sheep, a Substack newsletter on faith and mass media.With an illustrious career spanning over five decades, veteran Kannada actor Anant Nag is a force to be reckoned with in the film industry. Apart from several notable on-screen performances, Anant Nag has also served as a Karnataka Minister in the 1996 cabinet of then Chief Minister J.H. Patel. While revered by earlier generations for his versatility, today's audiences recognise him for his powerful cameo as Anand Ingalagi, the author of El Dorado, in the blockbuster KGF: Chapter 1 starring Rocking Star Yash. In an exclusive interview with Times Now, Anant Nag explains the reasons behind his limited film appearances in recent years. Kind of films being offered "I have stayed away from work—or perhaps, work has stayed away from me—because the scripts coming my way lack substance," he revealed candidly. "I am sorry to say this, but such scripts have drained my zeal for acting. At this phase of life, working purely for money does not make sense. That is why I have chosen to stay away unless I am offered a sensible role," he added. Following his performance as Anand Ingalagi, author of El Dorado in KGF Chapter 1 starring Rocking Star Yash, Anant Nag has been getting offers from various film industries, including Bollywood. However, the senior actor has been particular about his projects, declining roles that do not resonate with him. ALSO READ: ‘Ankur’ Title Was My Suggestion: Veteran Actor Anant Nag Recalls Winning Rs 1,000 Prize From Shyam Benegal | EXCLUSIVE Declining Jr NTR and Pawan Kalyan starrer films "Recently, I was approached for a film starring Jr. NTR, which I politely declined. Another offer came for a film featuring the current Deputy Chief Minister of Andhra Pradesh. I was asked to play the foster father of the lead character. When I learned that Pawan Kalyan was playing the hero, I was surprised. I wondered how he could manage acting while handling political responsibilities," Anant Nag said, recalling his own experience as a minister. "When I was in politics and made the Urban Development Minister in 1996, the then Chief Minister J.H. Patel had advised me to step away from acting, and I stayed away from films for over three and a half years." He also revealed that the same film cast (Pawan Kalyan starrer) Bobby Deol as the antagonist, with his character serving as the link between the protagonist and villain. Anant Nag explained that after KGF Chapter 1, he consciously avoided similar roles. "I even turned down KGF Chapter 2. I made it clear that I would not act in films of that genre again. While I am grateful for the offers, I have chosen to step back." Get Latest News Live on Times Now along with Breaking News and Top Headlines from Kannada, Entertainment News and around the world.
B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Axsome Therapeutics, Inc. ( NASDAQ:AXSM – Free Report ) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 9,241 shares of the company’s stock, valued at approximately $830,000. Several other institutional investors have also recently added to or reduced their stakes in AXSM. Vanguard Group Inc. increased its holdings in shares of Axsome Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock worth $298,474,000 after buying an additional 43,512 shares in the last quarter. XTX Topco Ltd increased its holdings in Axsome Therapeutics by 177.9% during the 2nd quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock valued at $902,000 after purchasing an additional 7,173 shares in the last quarter. Tri Locum Partners LP increased its holdings in Axsome Therapeutics by 198.4% during the 2nd quarter. Tri Locum Partners LP now owns 306,513 shares of the company’s stock valued at $24,674,000 after purchasing an additional 203,802 shares in the last quarter. Sofinnova Investments Inc. bought a new position in Axsome Therapeutics in the 2nd quarter valued at $24,971,000. Finally, Point72 Europe London LLP acquired a new position in Axsome Therapeutics in the second quarter worth $2,475,000. 81.49% of the stock is owned by institutional investors. Analysts Set New Price Targets AXSM has been the subject of a number of research reports. Robert W. Baird raised their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Needham & Company LLC reiterated a “buy” rating and set a $130.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, November 12th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Wells Fargo & Company began coverage on Axsome Therapeutics in a report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price objective on the stock. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $124.93. Axsome Therapeutics Price Performance Shares of AXSM opened at $98.68 on Friday. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The stock has a market cap of $4.78 billion, a P/E ratio of -15.11 and a beta of 1.26. The stock’s 50-day moving average price is $90.99 and its two-hundred day moving average price is $85.01. Axsome Therapeutics, Inc. has a 1 year low of $60.28 and a 1 year high of $105.00. Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the company earned ($1.32) earnings per share. On average, equities analysts predict that Axsome Therapeutics, Inc. will post -4.75 earnings per share for the current year. Insider Activity In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares in the company, valued at approximately $913,282.62. The trade was a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link . 22.40% of the stock is owned by company insiders. Axsome Therapeutics Company Profile ( Free Report ) Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. See Also Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
The US Congress has been attempting to “pull back the curtain” on secret research into UFOs - as our map reveals the 13 unexplained objects witnessed above Surrey . The hearing, titled “Unidentified Anomalous Phenomena: Exposing the Truth,” heard from several experts and a variety of witness accounts. Unidentified Anomalous Phenomena (UAP) is the new name for Unidentified Flying Objects (UFOs). Experts included government workers and a member of NASA’s UAP Independent Study Team. Michael Gold - former NASA associate administrator of space policy and partnerships and a member of the UAP study team - told the hearing that “the vast majority of UAP are drones”. However, he added that there are anomalies that must be studied and admitted that some of the UAPs observed “can move faster” than US submarines and “are being intelligently controlled”. In Surrey those looking to the skies have reported objects they just can't explain . These include a “black cigar-shaped object which descended from high altitude and swept across the sky” in April, 2021 above Puttenham. While over Guildford , in 2022 a person reportedly saw a 'purple light moving erratically, emitting a saucer-shaped vapour trail when changing directions'. Author and former Department of Defence official Luis Elizondo claimed that “advanced technologies not made by our government - or any other government - are monitoring sensitive military installations around the globe.” He insisted: “Let me be clear. UAP are real.” The hearing, jointly led by Chairs Nancy Mace and Glenn Grothman, was the second to investigate the phenomenon of UAP. “Americans deserve to understand what the government has learned about UAP sightings, and the nature of any potential threats these phenomena pose,” the co-chairs said in a statement. The hearing followed a long-awaited report released by NASA last year which studied previous sightings of UFOs (or UAPs) in the skies. While the report did not find any clear evidence that the sightings were alien, it did admit it was possible they could be. Last year the British spotter group UFO Identified documented a total of 395 sightings in the UK in 2023. That was a 20% drop from 497 UFO sightings in 2022 and also lower than in 2021 (413) and 2020 (484). Those figures include 13 sightings above Surrey, one last year, 10 in 2022, and two in 2021. You can see what UFO encounters have been reported where you live using our interactive map. UFO sightings documented in Surrey included: An aircraft “froze in the sky” above Staines for two hours in September last year, with “strange lights and contrails” around it and a bright sphere close by. A large circular object that appeared to be moving very slowly away from the moon, “too clear and close to be a star” was spotted above Farnham in October 2022. In Epsom in 2021, one person reported a 'submarine shaped object appeared at speed before rotating as it slowed down' Just under half of all documented sightings (48%) include photographic or video evidence. A quarter of all sightings (25%) were of a “star-like” object or objects, moving across the sky. The next most common sighting was of an unidentified object shaped like an “orb” (17%), “sphere”, (10%) and “cylinder” (9%). UFO Identified found that people in the North West had the best chance of seeing a UFO last year, with 41 sightings across the region, followed by the South East (40) and then the South West (39). Separate research by the UFO spotter website Enigma has documented more than 200,000 unexplained encounters above the skies of the USA. More UFOs have been spotted in California than any other US state, just over 28,000. California is followed by Florida (14,500), Texas (12,500) and New York (10,000). But those states have the highest populations in the US - meaning there are more people to watch the skies, and more likely that someone will see something they can’t explain. Taking population size into account, residents of New Mexico are most likely to have seen a UFO. For every 100,000 people, there are 162 sightings. That’s the equivalent of one in 618 people encountering a UFO.New study shows voting for Native Americans is harder than ever
JACKSONVILLE, Fla. — Greg McGarity had reason to be concerned. The Gator Bowl president kept a watchful eye on College Football Playoff scenarios all season and understood the fallout might affect his postseason matchup in Jacksonville. What if the Southeastern Conference got five teams into the expanded CFP? What if the Atlantic Coast Conference landed three spots? It was a math problem that was impossible to truly answer, even into late November. Four first-round playoff games, which will end with four good teams going home without a bowl game, had the potential to shake up the system. The good news for McGarity and other bowl organizers: Adding quality teams to power leagues — Oregon to the Big Ten, Texas to the SEC and SMU to the ACC — managed to ease much of the handwringing. McGarity and the Gator Bowl ended up with their highest-ranked team, No. 16 Ole Miss, in nearly two decades. "It really didn't lessen our pool much at all," McGarity said. "The SEC bowl pool strengthened with the addition of Texas and Oklahoma. You knew they were going to push traditional SEC teams up or down. Texas ended up pushing just about everyone down." The long waiting game was the latest twist for non-CFP bowls that have become adept at dealing with change. Efforts to match the top teams came and went in the 1990s and first decade of this century before the CFP became the first actual tournament in major college football. It was a four-team invitational — until this year, when the 12-team expanded format meant that four quality teams would not be in the mix for bowl games after they lose next week in the first round. "There's been a lot of things that we've kind of had to roll with," said Scott Ramsey, president of the Music City Bowl in Nashville, Tennessee. "I don't think the extra games changed our selection model to much degree. We used to look at the New York's Six before this, and that was 12 teams out of the bowl mix. The 12-team playoff is pretty much the same." Ramsey ended up with No. 23 Missouri against Iowa in his Dec. 30 bowl. A lot of so-called lesser bowl games do have high-profile teams — the ReliaQuest Bowl has No. 11 Alabama vs. Michigan (a rematch of last year's CFP semifinal), Texas A&M and USC will play in the Las Vegas Bowl while No. 14 South Carolina and No. 15 Miami, two CFP bubble teams, ended up in separate bowls in Orlando. "The stress of it is just the fact that the CFP takes that opening weekend," Las Vegas Bowl executive director John Saccenti said. "It kind of condenses the calendar a little bit." Bowl season opens Saturday with the Cricket Celebration Bowl. The first round of the CFP runs Dec. 20-21. It remains to be seen whether non-CFP bowls will see an impact from the new dynamic. They will know more by 2026, with a planned bowl reset looming. It could include CFP expansion from 12 to 14 teams and significant tweaks to the bowl system. More on-campus matchups? More diversity among cities selected to host semifinal and championship games? And would there be a trickle-down effect for everyone else? Demand for non-playoff bowls remains high, according to ESPN, despite increased focus on the expanded CFP and more players choosing to skip season finales to either enter the NCAA transfer portal or begin preparations for the NFL draft. "There's a natural appetite around the holidays for football and bowl games," Kurt Dargis, ESPN's senior director of programming and acquisitions, said at Sports Business Journal's Intercollegiate Athletics Forum last week in Las Vegas. "People still want to watch bowl games, regardless of what's going on with the playoff. ... It's obviously an unknown now with the expanded playoff, but we really feel like it's going to continue." The current bowl format runs through 2025. What lies ahead is anyone's guess. Could sponsors start paying athletes to play in bowl games? Could schools include hefty name, image and likeness incentives for players participating in bowls? Would conferences be willing to dump bowl tie-ins to provide a wider range of potential matchups? Are bowls ready to lean into more edginess like Pop-Tarts has done with its edible mascot? The path forward will be determined primarily by revenue, title sponsors, TV demand and ticket sales. "The one thing I have learned is we're going to serve our partners," Saccenti said. "We're going to be a part of the system that's there, and we're going to try to remain flexible and make sure that we're adjusting to what's going on in the world of postseason college football." Get local news delivered to your inbox!Michael Strahan hurt Terry Bradshaw's feelings within one minute of FOX NFL Sunday after joking that he'd wasted 10 seconds of his life . The Week 12 edition of FOX NFL Sunday was opened by artist Michael Buble, who narrated the opening credits following the release of his new Christmas song that came out on Nov. 18. FOX host Curt Menefee then took over as he said: "Thanks to five-time Grammy Award winner Michael Buble for opening the show, his new song 'Maybe This Christmas' with country star Carly Pearce is out right now. "As we welcome in Terry, Howie, Michael, and Jimmy... they didn't ask you (Bradshaw) to sing us a country song?" Bradshaw then explained how he was let down by analyst Howie Long, and replied: "Well I told them I would, but only with Howie and that was kind of the deal. Long then claimed that Americans needed a Bradshaw Christmas album, which the NFL legend disagreed with. Strahan then brutally interrupted and said: "Can I just say? That was 10 seconds of our lives we can never get back." Michael Strahan shows true colors with brutal Aaron Rodgers verdict on FOX NFL Sunday Michael Strahan forced to correct Terry Bradshaw on FOX NFL Sunday after confusing Chiefs remark Bradshaw then told Strahan: "Now Michael, that hurt my feelings." Strahan then apologized for his savage comment, but was dealt a dose of karma as Menefee moved things on to focus on the struggling New York teams, and added: "Speaking of Michael, you may want to cover your ears for this next segment." Strahan spent his entire 15-year NFL career with the New York Giants after being selected in the second round of the 1993 NFL Draft, and poetically won the Super Bowl in his final season (2007). The Giants won the Super Bowl again four years later after Eli Manning outclassed Tom Brady and the New England Patriots. However, the Giants are currently enduring a disastrous season and dropped to 2-9 on Sunday after losing 30-7 against the Tampa Bay Buccaneers. The Giants started second year quarterback Tommy DeVito against the Buccaneers, after agreeing to release Daniel Jones earlier this week. Jones didn't perform well enough to keep his starting role, and after signing a four-year, $160 million extension in 2023, the Giants made the decision to drop him to the bottom of the depth chart and end his stint with the team. Rather than wait until the end of the season to pursue other options, Jones requested to be released immediately. The situation became increasingly ugly on Sunday after the game, as rookie Giants wide receiver Malik Nabers was adamant that their losing streak had nothing to do with the quarterback and appeared to suggest it's a coaching issue. "It ain't the quarterback," Nabers said in the Giants locker room. "Same outcome when we had DJ (Daniel Jones) at quarterback. It ain't the quarterback." When asked if it was down to the play-calling, Nabers replied: "I don't know." Want to watch more live sports? Peacock has your favorite sports, shows, and more all in one place. Peacock offers plans starting at $7.99 so you can stream live sports like NFL, Premier League, and Big Ten Football.
Broncos hope to continue playoff push when they meet the banged-up Raiders
Slow growth, more uncertainty ahead in 2025
There's a Human Right Few of Us Think About, And We All Should Be CuriousB. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Illumina, Inc. ( NASDAQ:ILMN – Free Report ) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,441 shares of the life sciences company’s stock, valued at approximately $710,000. Several other institutional investors also recently modified their holdings of the business. Freemont Management S.A. bought a new stake in shares of Illumina in the 3rd quarter valued at about $1,565,000. Cetera Advisors LLC acquired a new stake in Illumina during the 1st quarter valued at approximately $610,000. Weybosset Research & Management LLC lifted its position in shares of Illumina by 92.0% in the 3rd quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after purchasing an additional 8,650 shares during the period. B. Riley Wealth Advisors Inc. boosted its stake in shares of Illumina by 176.3% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock valued at $749,000 after purchasing an additional 4,579 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Illumina by 3.6% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock worth $41,748,000 after buying an additional 13,725 shares during the period. Institutional investors own 89.42% of the company’s stock. Wall Street Analysts Forecast Growth ILMN has been the topic of a number of research analyst reports. Citigroup upped their price target on shares of Illumina from $155.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Barclays raised their target price on Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $164.00. Illumina Stock Performance Shares of Illumina stock opened at $140.14 on Friday. The company has a market cap of $22.23 billion, a PE ratio of -14.07 and a beta of 1.13. The business has a 50 day moving average price of $140.61 and a 200-day moving average price of $124.84. Illumina, Inc. has a 52 week low of $93.51 and a 52 week high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina ( NASDAQ:ILMN – Get Free Report ) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was down 3.5% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year. Illumina Company Profile ( Free Report ) Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. See Also Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. ( NASDAQ:ILMN – Free Report ). Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter .NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation ("Enovix" or the "Company") (NASDAQ: ENVX ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On December 16, 2024 , Enovix issued a press release "announc[ing] that CFO Farhan Ahmad has left the company and that it is searching for a new CFO." On this news, Enovix's stock price fell $0.56 per share, or 6.24%, to close at $8.42 per share on December 16, 2024 . Pomerantz LLP, with offices in New York , Chicago , Los Angeles , London , Paris , and Tel Aviv , is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud , breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com . Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext . 7980 SOURCE Pomerantz LLP